Palisade Bio (NASDAQ:PALI) Stock Rating Upgraded by LADENBURG THALM/SH SH

Palisade Bio (NASDAQ:PALI) was upgraded by equities researchers at LADENBURG THALM/SH SH to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

Other analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Palisade Bio from a “hold” rating to a “sell” rating in a research report on Saturday. HC Wainwright initiated coverage on Palisade Bio in a research note on Thursday, March 26th. They set a “buy” rating and a $7.00 price objective on the stock. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 9th. Stifel Nicolaus started coverage on Palisade Bio in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target on the stock. Finally, Wolfe Research started coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 price objective on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Palisade Bio currently has a consensus rating of “Buy” and an average target price of $10.20.

Palisade Bio Stock Up 5.0%

Shares of NASDAQ:PALI opened at $1.89 on Thursday. The company has a market cap of $328.07 million, a P/E ratio of -1.87 and a beta of 1.52. The business has a fifty day simple moving average of $1.95 and a 200-day simple moving average of $1.91. Palisade Bio has a 52 week low of $0.53 and a 52 week high of $2.85.

Palisade Bio (NASDAQ:PALI) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01). Sell-side analysts expect that Palisade Bio will post -0.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Palisade Bio

Hedge funds and other institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC acquired a new stake in shares of Palisade Bio in the 4th quarter valued at about $28,318,000. Commodore Capital LP bought a new stake in Palisade Bio in the fourth quarter valued at about $26,896,000. Janus Henderson Group PLC acquired a new stake in Palisade Bio during the fourth quarter valued at approximately $24,822,000. RA Capital Management L.P. acquired a new stake in Palisade Bio during the fourth quarter valued at approximately $16,742,000. Finally, Eversept Partners LP bought a new position in Palisade Bio during the 4th quarter worth approximately $12,670,000. Institutional investors own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.